Sobera on science-focused secondaries
Few firms invest in biotech and life sciences secondaries because it can be difficult to evaluate the portfolios, says Johannes Rabini, managing director of Berlin-based Sobera Capital.
17 November 2014•2 mins read
SECONDARIES INVESTOR
Register to unlock this content
Daily global secondaries market news and intelligence- Curated insights to keep you ahead of GP-led and LP-led secondaries
- Faster, data-driven decision making powered by our AI interface, 'Ask PEI'
- Access to proprietary research and reports
- Selected fund performance and investor activity data